How serious is postmenopausal bleeding?

October 11, 2017

CLEVELAND, Ohio (October 11, 2017) - If you're postmenopausal, you shouldn't be bleeding. The very definition of menopause is having gone more than 12 months without a period. So if you're still bleeding, something is wrong. Determining the seriousness of the problem and treating it, is not always evident. A presentation at The North American Menopause Society (NAMS) Annual Meeting in Philadelphia October 11-14, provides new evidence about the reliability and risks of various diagnostic approaches.

A number of conditions can lead to postmenopausal bleeding. Some of these conditions have few health consequences, while others could lead to cancer of some kind. Cancer of the endometrium is the most common type of gynecologic cancer in the US. In 2017, more than 60,000 cases of this cancer will occur, causing an estimated 10,470 deaths. Vaginal bleeding is the primary symptom in more than 90% of postmenopausal women with endometrial cancer, although the cause of bleeding for most postmenopausal women will be something much more benign, such as thinning of the vaginal walls or uterine lining as a result of fluctuating hormone levels. Depending on risk factors, 1-14% of women with postmenopausal bleeding will have endometrial cancer.

With such high stakes, there is a need to establish a standard of care that strives for 100% accuracy in correctly diagnosing the cause of the bleeding. In the past 25 years, the standard has changed substantially as new diagnostic techniques have been introduced, although no single method has proven appropriate for all patients.

"There continues to be confusion in the way postmenopausal bleeding is treated," says Dr. Steven Goldstein of the New York University School of Medicine, who will be presenting his recommendations on the standard of care for evaluating postmenopausal bleeding at the NAMS Annual Meeting. "It is not effective to just rely on routine triggers for further evaluation. Rather, an individualized assessment based on patient characteristics and risk factors is appropriate."

"This presentation will shed light on a very important issue and hopefully help educate healthcare providers on the need for individualized treatment," says Dr. JoAnn Pinkerton, NAMS executive director.

Drs. Goldstein and Pinkerton are available for interviews before the presentation at the Annual Meeting.
-end-
Founded in 1989, The North American Menopause Society (NAMS) is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging. Its multidisciplinary membership of 2,000 leaders in the field--including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education--makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging. To learn more about NAMS, visit http://www.menopause.org.

The North American Menopause Society (NAMS)

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.